Despite their potential as therapeutic targets, several challenges remain in targeting APBs. The heterogeneous nature of ALT-positive tumors complicates the development of universal therapies. Additionally, the redundancy of telomere maintenance mechanisms means that cancer cells might adapt to therapies targeting APBs by activating alternative pathways. Further research is needed to fully understand the molecular underpinnings of APBs and develop effective strategies to combat them.
